Orenitram®
Pulmonary Arterial Hypertension
Approved/CommercialDeveloped for United Therapeutics
Key Facts
Indication
Pulmonary Arterial Hypertension
Phase
Approved/Commercial
Status
Developed for United Therapeutics
Company
About Supernus Pharmaceuticals
Supernus Pharmaceuticals is a commercial-stage biopharma leader in CNS disorders, leveraging deep expertise in drug delivery and product development to build a diversified portfolio. The company has demonstrated consistent growth, earning recognition on lists like Forbes' America's Best Small Companies and Fortune's 100 Fastest Growing Companies. With a foundation of marketed products generating revenue, Supernus is strategically advancing mid- and late-stage pipeline candidates while maintaining a patient-centric culture and operational excellence.
View full company profileTherapeutic Areas
Other Pulmonary Arterial Hypertension Drugs
| Drug | Company | Phase |
|---|---|---|
| GSK3640254 | GSK plc | Phase 2 |
| PAH Program | Insmed | Phase 2b |
| Treprostinil (Remodulin) | United Therapeutics | Commercial |
| Treprostinil (Orenitram) | United Therapeutics | Commercial |
| Selexipag (Uptravi) | United Therapeutics | Commercial |
| Ralinepag | United Therapeutics | Phase 3 |
| Tadliq® (Tadalafil Oral Suspension) | CMP Pharma | Approved |